GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

 
• By Sue Sutter
Oncologic Drugs Advisry Committee Meeting has technical difficulties
FDA had to restart the ODAC meeting two hours after it originally began due to technical problems. • Source: Screen shot

More from United States

More from North America